MENU
+Compare
PBYI
Stock ticker: NASDAQ
AS OF
Jan 14 closing price
Price
$6.42
Change
+$0.18 (+2.88%)
Capitalization
323.51M

PBYI Puma Biotechnology Forecast, Technical & Fundamental Analysis

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients... Show more

Industry: #Biotechnology
PBYI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PBYI with price predictions
Jan 14, 2026

PBYI's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for PBYI moved out of overbought territory on December 30, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 instances where the indicator moved out of the overbought zone. In of the 35 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PBYI broke above its upper Bollinger Band on January 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on January 12, 2026. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for PBYI crossed bullishly above the 50-day moving average on December 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.807) is normal, around the industry mean (27.929). P/E Ratio (8.676) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (1.517) is also within normal values, averaging (329.547).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBYI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PBYI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PBYI is expected to report earnings to rise 30.71% to 27 cents per share on February 26

Puma Biotechnology PBYI Stock Earnings Reports
Q4'25
Est.
$0.27
Q3'25
Beat
by $0.05
Q2'25
Beat
by $0.06
Q4'24
Beat
by $0.32
Q3'24
Beat
by $0.13
The last earnings report on November 06 showed earnings per share of 20 cents, beating the estimate of 15 cents. With 351.84K shares outstanding, the current market capitalization sits at 323.51M.
A.I. Advisor
published General Information

General Information

operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10880 Wilshire Boulevard
Phone
+1 424 248-6500
Employees
185
Web
http://www.pumabiotechnology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IESFY185.158.15
+4.60%
Interconexion Electrica S.A. E.S.P. - ISA
DSITF1.69N/A
N/A
CURRYS PLC
UNTN22.00N/A
N/A
United Tennessee Bankshares, Inc.
NETTF30.07N/A
N/A
NetEase, Inc.
DMXCF0.90-0.02
-2.32%
District Metals Corp.

PBYI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with DSGN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then DSGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+2.88%
DSGN - PBYI
38%
Loosely correlated
+2.40%
MTNB - PBYI
35%
Loosely correlated
-4.57%
VSTM - PBYI
32%
Poorly correlated
-5.69%
RZLT - PBYI
30%
Poorly correlated
+9.68%
RNAC - PBYI
30%
Poorly correlated
-0.26%
More